newsfilter
← Latest News
GlobeNewswire·

Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System

  • Nutriband Inc. (NASDAQ:NTRB) received a Notice of Allowance from the USPTO on November 3, 2026, for commercial brand name trademarks for its lead abuse-deterrent fentanyl transdermal system.
  • The company plans to secure full trademark registration & intellectual property rights for these commercial brand names in the U.S. & internationally.
  • Extensive naming research was conducted to ensure the proprietary name is distinct from existing medications to prevent look-alike/sound-alike errors & enhance patient safety.
  • Nutriband intends to submit its proposed global brand name to the FDA, EMA, & other international regulatory bodies via preapproval pathways prior to formal NDA or MAA filings.
  • The lead product utilizes proprietary AVERSA™ technology to deter intentional abuse & misuse while reducing the risk of accidental exposure.
  • The abuse-deterrent fentanyl transdermal system is projected to achieve peak annual U.S. sales between $80 million & $200 million.
  • AVERSA™ technology incorporates aversive agents into patches to prevent abuse, diversion, misuse, & accidental exposure of opioids & stimulants.
  • The AVERSA™ technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries, including the U.S., Europe, Japan, Korea, Russia, China, Canada, Mexico, & Australia.
  • Nutriband is currently focused on the U.S. market but targets major medical markets worldwide to address the global unmet need for pain management.
  • Nutriband Inc. develops a portfolio of transdermal pharmaceutical products, with the abuse-deterrent fentanyl patch being its primary development focus.
Company
Nutriband Inc.
Keywords
Nasdaq:NTRB, Nutriband Inc., aversa, USPTO, transdermal, Russell, Pharmaceuticals, patent, nasdaq, IP, Index